Home testing devices could monitor epilepsy drug levels, reduce clinical visits

December 10, 2013

Medications remain the mainstay of epilepsy treatment, and to date there are no FDA-approved devices that provide an accurate means of detection for generalized tonic-clonic seizures (GTCS), or convulsions, during activities of daily living. Two new studies presented at the American Epilepsy Society's 67th Annual Meeting in Washington D.C. provide data that warrants the development of non-invasive devices with the capability to signal the onset of an epileptic seizure and could be crucial to optimal patient dosing.

Interim analysis that aims to validate a seizure detection software algorithm was presented to support the development of a non-invasive detection device with the ability to measure electromyography (EMG) signals (Poster 2.037 / Abstract 1750832). Patients in this study were asked to wear an arm-device that detected all GTCS within 30 seconds of arm motor action. Thirty-three patients with a history of seizures were enrolled in the study while in the hospital Epilepsy Monitoring Unit for routine EEG monitoring.

"Our study demonstrates the feasibility to detect generalized tonic-clonic seizures with an arm device analyzing muscle activity during . We were able to capture the GTCS through analysis of EMG signals and confirmed these using video-EEG (vEEG) recordings. The was optimized using baseline measurements of maximum voluntary muscle contraction (MVC). In all but one instance that a GTCS was recorded by vEEG, it was also captured by EMG, proving the device to be over 95% sensitive in detecting GTCSs," said Akos Szabo, MD, the lead researcher of the study.

The results determined that the seizure detection algorithm appeared superior to the other devices currently under investigation or currently commercialized. Only one false alarm was triggered during 1,400 hours of activities of normal living.

In a related study conducted by a research team at the University of Texas Houston, a study testing bio-nano-chips (BNCs) as a non-invasive, repeatable and adaptable alternative to serial serum antiepileptic drug measurements (Platform A.09 / Abstract 1750229). This study provides a report on progress towards developing a realistic saliva-based BNC system for two commonly used antiepileptic drugs – phenytoin (PHT) and phenobarbital (PHB). The purpose of this technology is to allow a patient or their caregiver to detect the level of antiepileptic drugs in their system and monitor their drug levels outside of their doctor's office.

"These bio-nano-chips, or "labs on a chip" as we like to call them, are a new generation of compact, programmable chemical processors that will satisfy the urgent need for non-invasive, adaptable and cost effective alternatives to blood test," said Giridhar P. Kalamangalam, MD.

The BNC calibration signals were robust and provided low reliable limits of detection, and compared favorably to the in-lab gold standards. Further work will aim to produce a practical point of care diagnostic, eventually a hand-held device the size of a credit card that will empower patients to monitor drug intake on their own.

Explore further: Study reports seizure-freedom in 68 percent of juvenile myoclonic epilepsy patients

Related Stories

Implantable medical device for epilepsy

December 3, 2013

(Medical Xpress)—Physicians at the University of Rochester Medical Center (URMC) Strong Epilepsy Center were involved in the recent approval of a new treatment for epilepsy. The implantable medical device – called the ...

Getting to grips with seizure prediction

November 7, 2013

A device that could predict when a person with epilepsy might next have a seizure is one step closer to reality thanks to the development of software by researchers in the USA. Details are to be published in a forthcoming ...

Recommended for you

Research reveals how the brain remembers fearful experiences

February 20, 2017

Understanding how the brain remembers can one day shed light on what went wrong when memory fails, such as it occurs in Alzheimer's disease. Researchers at Baylor College of Medicine and Rice University reveal for the first ...

Mercury in fish, seafood may be linked to higher risk of ALS

February 20, 2017

Eating fish and seafood with higher levels of mercury may be linked to a higher risk of amyotrophic lateral sclerosis (ALS), according to a preliminary study released today that will be presented at the American Academy of ...

Stem cell transplants may help some with multiple sclerosis

February 20, 2017

(HealthDay)—Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study ...

Hope for new treatment for Huntington's disease

February 20, 2017

Researchers working at Karolinska Institutet in Sweden and University of Southern Denmark have managed to produce short synthetic DNA analogues – oligonucleotides – that bind directly to the gene that is mutated in Huntington's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.